ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ: AMGN) for $120 per share. Shares…
Paul Ausick ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28% gain…
U.S. equity markets opened lower this morning on relatively little economic data. In Europe, Germany reported that industrial production rose 1.2%, while a house price index in the U.K.rose 1.1% month-over-month. In…
ThinkstockThe world of pharmaceuticals may have faced a patent cliff in recent years, but brand name drugs are still generating billions upon billions in annual sales in the United States alone. Some…
U.S. equity markets opened lower this morning following a weaker-than-expected employment report from ADP and concern that Friday’s report from the Bureau of Labor Statistics will follow the ADP lead (more coverage…
Biotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many investors, what…
Investors and traders are always on the lookout for fresh research ideas from Wall Street that will lead to higher income or more profits. 24/7 Wall St. reviews many fresh research calls…
ThinkstockDrug giant Pfizer Inc. (NYSE: PFE) this morning reported adjusted earnings and revenues that missed analysts estimates, and the stock is down more than 3%. Last week competitor Amgen Inc. (NASDAQ: AMGN)…
Investors love dividends. This one investing component has comprised a major portion of total returns through time. The trend in recent years has been for companies to pay dividends and keep raising…
Jon OggInvestors frequently get to see the analyst upgrades and Buy ratings from Wall St. firms. They often do not get to see or they overlook the analyst downgrades and lists of…
Jon OggArgus offers what is truly considered to be independent investment research. This gives the firm the lack of any or most of the traditional conflicts of interest that can be the case…
Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to get exposure…
Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well…
The Fidelity Contrafund has released its 2012 annual report for its shareholders. While the date is December 31, 2012, and the asset size is listed as more than $84 billion as of…
Jon OggThese are some of this Monday’s top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Amgen Inc. (NASDAQ: AMGN) cut to Market Perform at William Blair. AOL Inc.…
